產品列表

我們提供RUO和GMP兩種級別的Anti-CD抗體，助力您從發現到臨床階段的研究。

• RUO級Anti-CD抗體

  產品編號	名稱	數量	價格	操作
  A02199	Anti-Human CD3 Antibody (OKT3), mAb, Mouse		￥400.00 100 μg
  A02211	Anti-Human CD4 Antibody (F001), mAb, Mouse		￥400.00 100 μg
  A02212	Anti-Human CD8 Antibody (F002), mAb, Mouse		￥400.00 100 μg
  A02213	Anti-Human CD28 Antibody (F105), mAb, Mouse		￥400.00 100 μg

• GMP級Anti-CD抗體

  產品編號	名稱	數量	價格	操作
  GMPA02199	GMP Anti-Human CD3 Antibody (OKT3), mAb, Mouse		- 100 μg 1 mg
  GMPA02213	GMP Anti-Human CD28 Antibody (F105), mAb, Mouse		- 100 μg 1 mg

• 新品預告

  產品編號	名稱	訂購
  GMPA02211	GMP Anti-Human CD4 Antibody (F001), mAb, Mouse	咨詢
  GMPA02212	GMP Anti-Human CD8 Antibody (F002), mAb, Mouse	咨詢

*沒找到您需要的GMP級Anti-CD抗體？ 聯系我們并提供RUO級產品貨號或CD分子名稱。金斯瑞的GMP蛋白平臺可將RUO級目錄產品快速轉化為GMP級。

*金斯瑞可根據您的要求提供抗體標記。包括 PE、FITC、iFluor 488、iFuor 555、iFuor 647 和Biotin。如需標記Anti-CD抗體，請聯系我們。

RUO 對比 GMP

• 質控放行標準

  項目	GMP*級抗體	RUO級抗體
  濃度	5.0 ± 0.5 mg/mL	1.0 ± 0.1 mg/mL
  外觀	澄清、無色液體	澄清、無色液體
  純度	SEC-HPLC：≥ 95%	SEC-HPLC：≥ 95%
  內毒水平	< 0.1 EU/mg	< 0.5 EU/μg
  活性	經驗證	經驗證
  鑒定	經質譜方法驗證，序列與理論序列完全一致	/
  HCP殘留	≤ 100.0 ng/mg	/
  HCD殘留	≤ 10.0 pg/mg	/
  Protein A殘留	≤ 10.0 ng/mg	/
  無菌	無菌	/

  *GMP 級是金斯瑞用來描述在符合GMP規范的環境中生產的CD抗體的一個特定術語。該抗體生產遵循GMP的指導原則，具有嚴格的過程控制和完整的文件記錄。金斯瑞可提供文件記錄，現場審計，及其它可幫助您的項目在特定區域進行申報的支持。詳細了解我們的 GMP的能力。

• GMP級Anti-CD抗體特色

  體外細胞培養可用性	GMP生產合規性	高穩定性和批間一致性
  無菌無動物源	可追溯文件記錄	長期穩定性研究
  超低內毒水平（< 0.1 EU/mg）	符合GMP生產規范	加速穩定行研究
  HCD, HCP, Protein A殘留控制	嚴格的質量控制和放行檢測	凍融穩定性研究
  高純度及高親和力	可提供審計及法規相關支持	批次間質量一致

應用案例

• 抗人CD3和CD28抗體激活T細胞

  抗CD3和抗CD28抗體與 T 細胞表面表達的相應CD標志物結合，分別為T細胞激活提供第一和第二信號。共刺激的激活信號誘導T細胞快速增殖，在適應性免疫反應和免疫治療中起著至關重要的作用。

  • 抗人CD3和CD28抗體激活T細胞快速增殖
    

    Figure 1. GMP Anti-Human CD3 Antibody (OKT3), mAb, Mouse (Cat. No. GMPA02199) was used for primary T cell activation together with anti-Human CD28 antibody. The percentage of activated T cells were measured by flow cytometry. Data showed that GenScript GMP Anti-Human CD3 Antibody (OKT3), mAb, Mouse outperformed the competing products in activating primary T cells.

  • 抗人CD3和CD28抗體刺激報告細胞系信號響應
    

    Figure 2. CHO-K1/CD80 cells were plated 15 h before adding Jurkat/IL-2-Luc Promoter cells, then Jurkat/IL-2-Luc Promoter cells were stimulated with a serial of concentrations of Anti-Human CD3 Antibody (OKT3), mAb, Mouse (Cat. No. A02199) for 5 h. Receptor-mediated signaling induced luminescence via activation of the IL-2 pathway.

    Figure 3. Jurkat/IL-2-Luc Promoter cells were co-stimulated with a serial of concentrations of Anti-Human CD28 Antibody (F105), mAb, Mouse (Cat. No. A02213) and 1 μg/mL of Anti-Human CD3 Antibody (OKT3), mAb, Mouse (Cat. No. A02199) for 5 h. Receptor-mediated signaling induced luminescence via activation of the IL-2 pathway.

  • 原代T細胞激活鑒定和細胞因子分泌檢測
    

    Figure 4. Primary T cells were stimulated with 5 μg/mL of Anti-Human CD3 Antibody (OKT3), mAb, Mouse (Cat. No. A02199) (left), competing anti-Human CD3 antibody (middle), negative control (NC, right) as well as anti-Human CD28 antibody (all panels) for 72 h, respectively. CD25/CD69 expression was detected by flow cytometry to characterize cell activation.

    

    Figure 5. Primary T cell clumping was observed by a microscope after T cell activation (72 h) (right) using Anti-Human CD3 Antibody (OKT3), mAb, Mouse (Cat. No. A02199) and Anti-Human CD28 Antibody (F105), mAb, Mouse (Cat. No. A02213). The inactivated T cells were presented on the left image.

    

    Figure 6. Interferon γ (IFN-γ) secretion by activated primary T cells using Anti-Human CD3 Antibody (OKT3), mAb, Mouse (Cat. No. A02199) and anti-Human CD28 antibody. Data showed that GenScript anti-Human CD3 antibody outperformed competing product.

    Figure 7. Interferon γ (IFN-γ) secretion by activated primary T cells using Anti-Human CD28 Antibody (F105), mAb, Mouse (Cat. No. A02213) and anti-Human CD3 antibody. Data showed that GenScript anti-Human CD28 antibody outperformed competing product.

• 抗人CD4和CD8抗體用于PBMC染色鑒定T細胞亞群

  抗CD抗體特異性識別細胞上表達的CD分子標志物，可用于進行細胞分群或功能鑒定。例如，CD4和CD8是PBMC染色中識別CD4+輔助T細胞和CD8+細胞毒性T細胞的常用標志物。

  

  Figure 8. Human peripheral blood mononuclear cells (PBMCs) were stained with Anti-Human CD4 Antibody (F001), mAb, Mouse (Cat. No. A02211) (left), competing anti-human CD4 antibody (middle), mouse IgG1 negative control (NC, right) as well as with anti-Human CD3 [BV510] antibody (all panels). Flow cytometry was performed for further analysis. Cell debris and dead cells were excluded from the analysis based on scatter signals and 7-AAD.

  

  Figure 9. Human peripheral blood mononuclear cells (PBMCs) were stained with Anti-Human CD8 Antibody (F002), mAb, Mouse (Cat. No. A02122) (left), competing anti-Human CD8 antibody (middle), mouse IgG1 negative control (right) as well as with anti-Human CD3 [BV510] antibody (all panels). Flow cytometry was performed for further analysis. Cell debris and dead cells were excluded from the analysis based on scatter signals and 7-AAD.

產品性能

• 高批間一致性
  

  Figure 10. Lot-to-lot consistency was tested using four batches of Anti-Human CD3 Antibody (OKT3), mAb, Mouse (Cat. No. A02199) on Jurkat/IL-2-Luc Promoter cells. Receptor-mediated signaling induced luminescence via activation of the IL-2 pathway. Data showed that GenScript Anti-Human CD3 Antibody (OKT3), mAb, Mouse (Cat. No. A02199) has a high lot-to-lot consistency.

  Figure 11. Lot-to-lot consistency was tested using four batches of Anti-Human CD28 Antibody (F105), mAb, Mouse (Cat. No. A02213) on Jurkat/IL-2-Luc Promoter cells. Receptor-mediated signaling induced luminescence via activation of the IL-2 pathway. Data showed that GenScript Anti-Human CD28 Antibody (F105), mAb, Mouse (Cat. No. A02213) has a high lot-to-lot consistency.

• 高穩定性
  

  Figure 12. Stability of GenScript GMP Anti-Human CD8 Antibody (F002), mAb, Mouse (Cat. No. GMPA02212) was tested. The data of long-term stability, accelerated stability, and freeze-thaw cycle stability indicated that this GMP antibody is very stable under various storage conditions.